Breast cancer prognosis by combinatorial analysis of gene expression data

被引:215
|
作者
Alexe G. [1 ,2 ,3 ]
Alexe S. [1 ]
Axelrod D.E. [4 ,5 ]
Bonates T.O. [1 ]
Lozina I.I. [1 ]
Reiss M. [5 ,6 ]
Hammer P.L. [1 ]
机构
[1] RUTCOR (Rutgers University Center for Operations Research), Piscataway, NJ
[2] Computational Biology Center, TJ Watson IBM Research, Yorktown Heights, NY
[3] The Simons Center for Systems Biology, Institute for Advanced Study, Princeton, NJ
[4] Department of Genetics, Rutgers University, Piscataway, NJ
[5] The Cancer Institute of New Jersey, New Brunswick, NJ
[6] Division of Medical Oncology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
关键词
Breast Cancer; Negative Case; Negative Pattern; Positive Pattern; Prognostic System;
D O I
10.1186/bcr1512
中图分类号
学科分类号
摘要
Introduction: The potential of applying data analysis tools to microarray data for diagnosis and prognosis is illustrated on the recent breast cancer dataset of van't Veer and coworkers. We re-examine that dataset using the novel technique of logical analysis of data (LAD), with the double objective of discovering patterns characteristic for cases with good or poor outcome, using them for accurate and justifiable predictions; and deriving novel information about the role of genes, the existence of special classes of cases. and other factors. Method: Data were analyzed using the combinatorics and optimization-based method of LAD, recently shown to provide highly accurate diagnostic and prognostic systems in cardiology, cancer proteomics, hematology, pulmonology, and other disciplines. Results: LAD identified a subset of 17 of the 25,000 genes, capable of fully distinguishing between patients with poor, respectively good prognoses. An extensive list of 'patterns' or 'combinatorial biomarkers' (that is, combinations of genes and limitations on their expression levels) was generated, and 40 patterns were used to create a prognostic system, shown to have 100% and 92.9% weighted accuracy on the training and test sets, respectively. The prognostic system uses fewer genes than other methods, and has similar or better accuracy than those reported in other studies. Out of the 17 genes identified by LAD, three (respectively, five) were shown to play a significant role in determining poor (respectively, good) prognosis. Two new classes of patients (described by similar sets of covering patterns, gene expression ranges, and clinical features) were discovered. As a by-product of the study, it is shown that the training and the test sets of van't Veer have differing characteristics. Conclusion: The study shows that LAD provides an accurate and fully explanatory prognostic system for breast cancer using genomic data (that is, a system that, in addition to predicting good or poor prognosis, provides an individualized explanation of the reasons for that prognosis for each patient). Moreover, the LAD model provides valuable insights into the roles of individual and combinatorial biomarkers, allows the discovery of new classes of patients, and generates a vast library of biomedical research hypotheses. © 2006 Alexe et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [31] Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test
    Kronenwett, Ralf
    Bohmann, Kerstin
    Prinzler, Judith
    Sinn, Bruno V.
    Haufe, Franziska
    Roth, Claudia
    Averdick, Manuela
    Ropers, Tanja
    Windbergs, Claudia
    Brase, Jan C.
    Weber, Karsten E.
    Fisch, Karin
    Mueller, Berit M.
    Schmidt, Marcus
    Filipits, Martin
    Dubsky, Peter
    Petry, Christoph
    Dietel, Manfred
    Denkert, Carsten
    BMC CANCER, 2012, 12
  • [32] Comprehensive gene expression analysis predicts postoperative prognosis of ER-negative breast cancer.
    Nagahata, T
    Onda, M
    Fujimoto, T
    Tsumagari, K
    Nagai, H
    Kasumi, F
    Emi, M
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S81 - S81
  • [33] Coupled two-way clustering analysis of breast cancer and colon cancer gene expression data
    Getz, G
    Gal, H
    Kela, I
    Notterman, DA
    Domany, E
    BIOINFORMATICS, 2003, 19 (09) : 1079 - 1089
  • [34] Abnormal gene expression leads to poor prognosis in breast cancer patients in Bihar
    Anshu A.K.
    Nath A.
    Prinyanka
    Sinha N.
    Sinha P.
    Sinha S.
    Singh J.K.
    Comparative Clinical Pathology, 2016, 25 (4) : 763 - 768
  • [35] The rapamycin-regulated gene expression signature determines prognosis for breast cancer
    Argun Akcakanat
    Li Zhang
    Spiridon Tsavachidis
    Funda Meric-Bernstam
    Molecular Cancer, 8
  • [36] Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer
    Toyama, T
    Iwase, H
    Yamashita, H
    Hara, Y
    Omoto, Y
    Sugiura, H
    Zhang, ZH
    Fujii, Y
    CANCER LETTERS, 2003, 189 (01) : 97 - 102
  • [37] Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes
    Gyorffy, B.
    Bottai, G.
    Fleischer, T.
    Munkacsy, G.
    Paladini, L.
    Bressen-Dale, A. L.
    Kristensen, V.
    Santarpia, L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S41 - S41
  • [38] The rapamycin-regulated gene expression signature determines prognosis for breast cancer
    Akcakanat, Argun
    Zhang, Li
    Tsavachidis, Spiridon
    Meric-Bernstam, Funda
    MOLECULAR CANCER, 2009, 8 : 75
  • [39] Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes
    Gyorffy, Balazs
    Bottai, Giulia
    Fleischer, Thomas
    Munkacsy, Gyongyi
    Budczies, Jan
    Paladini, Laura
    Borresen-Dale, Anne-Lise
    Kristensen, Vessela N.
    Santarpia, Libero
    INTERNATIONAL JOURNAL OF CANCER, 2016, 138 (01) : 87 - 97
  • [40] Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer
    Alberto Calabrò
    Tim Beissbarth
    Ruprecht Kuner
    Michael Stojanov
    Axel Benner
    Martin Asslaber
    Ferdinand Ploner
    Kurt Zatloukal
    Hellmut Samonigg
    Annemarie Poustka
    Holger Sültmann
    Breast Cancer Research and Treatment, 2009, 116 : 69 - 77